Living meta-analysis and evidence synthesis of therapies for COVID-19

click on circles to display study description...

ACTIV-3 Critical Care, 2022 NCT04843761

aviptadil (n=-9) vs. placebo (n=-9)

randomized controlled trial   risk of bias NA

Studied treatment

Control treatment

Patients

COVID-19 severe or critically

Method

Remark

the Data Safety and Monitoring Board (DSMB) of the ACTIV-3b (TESICO) clinical trial recommended halting analysis of Zyesami (aviptadil) in critical Covid-19 patients due to futility